Fig. 3From: SLC27A2 is a potential immune biomarker for hematological tumors and significantly regulates the cell cycle progression of diffuse large B-cell lymphomaDLBCL Cell Cycle Experiment. The cell cycle results showed that compared with the OCI-LY1 + SLC27A2-siRNA-817 group, the G1 phase cells were significantly reduced, the S phase cells were significantly increased, and the G2 phase cells were significantly increased (A, B). Therefore, low expression of SLC27A2 significantly promoted the progression of the DLBCL cell cycleBack to article page